Allogeneic cell therapy production trends: driving tomorrow’s success
Sponsor
Live30 webinars are thirty-minute presentations designed to update you on the latest innovations, applications, and data in a fast yet interactive format.
Allogeneic cell therapies have some clear advantages over autologous cell therapies including cell source, cost to manufacture, process success rate, speed, and availability of therapy to patients.
As more and more therapies come out of the lab and head for the clinic, the process and solutions required to bring these drug products safely and quickly to market must keep pace.
Join us for this CGTI Live 30 to hear from Tom Bongiorno, PhD, field application scientist at Corning Life Sciences, about current trends in allogeneic stem cell therapy production, including proven and emerging technology platforms, optimized surface selection, and process best practices.
- Review current trends in allogeneic stem cell therapy production
- Overview of current technology platforms, including key benefits for each platform and their role within optimized workflows
- Introduction to new technology platforms and overview of features
- Surface selection guidance aligned with project goals
- Workflow process best practices
SPEAKERS
You might also like
Same-section spatial multiomics: a platform for detailed analysis of the solid tumor TME
Specifications don’t tell the whole story: how to choose GMP process and QC equipment
Quadplex dPCR as a tool to analyze genome integrity and heterogeneity in gene therapy drug products
Precision in production: optimizing monitoring and quality control for high-value plasmids
